RESUMEN
Na(+)/H(+) exchanger (NHE) proteins perform a variety of functions in the kidney and are differentially distributed among nephron segments. The purpose of this study was to identify NHE isoforms in murine M-1 cells as a model of cortical collecting duct principal cells. It was found that mRNAs corresponding to NHE1, NHE2, and NHE4 are expressed in M-1 cells. NHE-dependent regulation of intracellular pH (pH(i)) was investigated in the absence of extracellular HCO. Application of a 20 mM NH(4)Cl pulse resulted in a reversible intracellular acidification from which recovery was partially inhibited by application of 1 mM amiloride to either the apical or the basolateral membranes and was abolished when amiloride was applied to both sides of the monolayers, which suggests that NHEs are expressed in both the apical and the basolateral cell membranes of M-1 cells. The purinergic agonists ATP and benzoylbenzoyl-ATP caused a reduction of pH(i) when applied to the apical membrane, which suggests pH(i) may be influenced by extracellular nucleotides in the luminal fluid of the cortical collecting duct.
Asunto(s)
Corteza Renal/metabolismo , Túbulos Renales Colectores/metabolismo , Intercambiadores de Sodio-Hidrógeno/biosíntesis , Animales , Transporte Biológico Activo/efectos de los fármacos , Línea Celular , Membrana Celular/efectos de los fármacos , Membrana Celular/metabolismo , Concentración de Iones de Hidrógeno , Isomerismo , Ratones , Nucleótidos/farmacología , Oligonucleótidos Antisentido/farmacología , ARN Mensajero/biosíntesis , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Sodio/metabolismo , Intercambiadores de Sodio-Hidrógeno/metabolismoRESUMEN
The mu-opioid agonist loperamide is an antidiarrhoeal drug which inhibits intestinal motility and secretion. Its anti-absorptive effects are less well investigated, but may be mediated through calmodulin. We have investigated further the effect of loperamide on the intestinal Na+-dependent D-glucose transporter (SGLT1). Brush-border membrane vesicles were prepared from mouse small intestine, and uptake of [3H]glucose was measured. Na+-dependent glucose uptake displayed the typical overshoot at 34 s; the peak value was 1.6 nmol mg(-1). The overshoot disappeared in the presence of phlorizin or when Na+ was replaced by K+. Extravesicular loperamide dose-dependently inhibited SGLT1 activity with an IC50 value of 450 micromol L(-1). Loperamide displayed a mixed inhibition type: the apparent Vmax decreased from 0.9 to 0.5 nmol mg(-1)/15 s, the apparent Km increased from 0.23 to 1.13 mmol L(-1) glucose. Na+ kinetics were more complex, but loperamide inhibited net glucose uptake by 90% at 100 mmol L(-1) Na+. Glucose uptake was unchanged by agents affecting calmodulin activity. Loperamide inhibited intestinal Na+, K+-ATPase activity, whilst sucrase activity was unaffected. SGLT1 activity was inhibited by loperamide, but this effect was not mediated through calmodulin. As this action is only evident at high concentrations of loperamide a nonspecific mechanism may be involved.
Asunto(s)
Antidiarreicos/farmacología , Intestino Delgado/efectos de los fármacos , Loperamida/farmacología , Proteínas de Transporte de Monosacáridos/efectos de los fármacos , Animales , Calmodulina/farmacología , Relación Dosis-Respuesta a Droga , Glucosa/farmacocinética , Intestino Delgado/fisiología , Masculino , Ratones , Proteínas de Transporte de Monosacáridos/metabolismoRESUMEN
The properties of ATP-sensitive K+ (K(ATP)) channels were explored in the electrofusion-derived, glucose-responsive, insulin-secreting cell line BRIN-BD11 using patch-clamp techniques. In intact cells, K(ATP) channels were inhibited by glucose, the sulfonylurea tolbutamide, and the imidazoline compounds efaroxan and phentolamine. Each of these agents initiated insulin secretion and potentiated the actions of glucose. K(ATP) channels were blocked by ATP in a concentration-dependent manner and activated by ADP in the presence of ATP. In both intact cells and excised inside-out patches, the K(ATP) channel agonists diazoxide and pinacidil activated channels, and both compounds inhibited insulin secretion evoked by glucose, tolbutamide, and imidazolines. The mechanisms of action of imidazolines were examined in more detail. Pre-exposure of BRIN-BD11 cells to either efaroxan or phentolamine selectively inhibited imidazoline-induced insulin secretion but not the secretory responses of cells to glucose, tolbutamide, or a depolarizing concentration of KCl. These conditions did not result in the loss of depolarization-dependent rises in intracellular Ca2+ ([Ca2+]i), K(ATP) channel operation, or the actions of either ATP or efaroxan on K(ATP) channels. Desensitization of the imidazoline receptor following exposure to high concentrations of efaroxan, however, was found to result in an increase in SUR1 protein expression and, as a consequence, an upregulation of K(ATP) channel density. Our data provide 1) the first characterization of K(ATP) channels in BRIN-BD11 cells, a novel insulin-secreting cell line produced by electrofusion techniques, and 2) a further analysis of the role of imidazolines in the control of insulin release.
Asunto(s)
Adenosina Trifosfato/farmacología , Antagonistas Adrenérgicos alfa/farmacología , Benzofuranos/farmacología , Imidazoles/farmacología , Insulina/metabolismo , Islotes Pancreáticos/fisiología , Canales de Potasio/fisiología , Adenosina Difosfato/farmacología , Animales , Fusión Celular , Línea Celular , Diazóxido/farmacología , Glucosa/farmacología , Secreción de Insulina , Insulinoma , Islotes Pancreáticos/efectos de los fármacos , Islotes Pancreáticos/metabolismo , Potenciales de la Membrana/efectos de los fármacos , Neoplasias Pancreáticas , Fentolamina/farmacología , Pinacidilo/farmacología , Tolbutamida/farmacología , Células Tumorales CultivadasRESUMEN
Human embryonal carcinoma (EC) cells typically require high cell densities to maintain their characteristic phenotype; they are generally subject to differentiation when cultured at low cell densities, marked by changes in morphology and expression of the surface antigen, SSEA-1. To test whether cadherin mediated cell-to-cell adhesion may be responsible for maintaining an EC phenotype we ascertained that human EC cells generally express E- and P-cadherins, and are subject to cadherin mediated, Ca2+ dependent aggregation. However, in the NTERA2 human EC cell line, inhibition of cadherin mediated adhesion by culture in low levels of Ca2+ did not result in the changes typically seen under low cell density conditions. Low Ca2+ levels also did not affect the pattern of differentiation in these cells following induction with retinoic acid. Therefore, cadherin-mediated cell adhesion does not appear to play a role in maintaining an EC phenotype. On the other hand, culture at both low cell density and in the absence of Ca2+ did result in changes in the patterns of cadherin expression suggesting a feedback regulatory effect of cell-to-cell adhesion. Further, lithium which inhibits the cytoplasmic kinase GSK3beta and hence influences beta-catenin levels did cause differentiation of NTERA2 cells. However, consideration of the phenotype of the resultant cells suggested that this effect may be because of lithium mimicking activation of a Wnt signalling pathway, rather than an effect on signalling consequent upon cadherin mediated cell to cell adhesion.
Asunto(s)
Cadherinas/metabolismo , Adhesión Celular , Células Madre Neoplásicas/metabolismo , Transactivadores , Cadherinas/fisiología , Calcio/farmacología , Recuento de Células , Proteínas del Citoesqueleto/metabolismo , Desmoplaquinas , Relación Dosis-Respuesta a Droga , Células Madre de Carcinoma Embrionario , Citometría de Flujo , Humanos , Litio/farmacología , Células Madre Neoplásicas/fisiología , Fenotipo , Factores de Tiempo , alfa Catenina , beta CateninaRESUMEN
The sulphonylurea receptor (SUR) is the site of action for sulphonylurea derivatives such as glibenclamide, which are widely used as oral hypoglycaemic agents. Sulphonylureas have also been shown to affect urine flow and salt excretion by the kidney; therefore, the use of these drugs may have important implications for the pharmacological manipulation of renal salt handling. The purpose of the present investigation was to increase our understanding of the possible role of SUR in the regulation of renal function by determining the distribution of SUR isoforms within mouse kidney. Immunostaining with anti-SUR antisera revealed specific staining of SUR2B in distal nephron segments of mouse kidney. A diffuse, low level staining was observed in proximal tubules in the inner cortical region. No evidence was found for the presence of SUR2B in intra-renal blood vessels. Reverse-transcription polymerase chain reaction and Western blotting experiments indicated that SUR2B is the only known isoform expressed. These data demonstrate that SUR2B in mouse kidney is expressed in tubule regions that are critical in determining renal salt excretion.
Asunto(s)
Transportadoras de Casetes de Unión a ATP , Riñón/metabolismo , Canales de Potasio de Rectificación Interna , Canales de Potasio/biosíntesis , Receptores de Droga/biosíntesis , Secuencia de Aminoácidos , Animales , Western Blotting , Cricetinae , Cartilla de ADN , Inmunohistoquímica , Isomerismo , Riñón/fisiología , Masculino , Ratones , Datos de Secuencia Molecular , Canales de Potasio/genética , Ratas , Receptores de Droga/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Receptores de SulfonilureasRESUMEN
Following subcellular fractionation of platelet homogenates and Western blotting, two groups of alpha-subunits of trimeric G-proteins could be distinguished. Group 1 consisted of alpha(i)-2, alpha(i)-3, alpha(z), alpha(s), and alpha(q) and was predominantly localized in membranes. Group 2 consisted of alpha16 and alph12 and was predominantly localized in the cytosol. Plasma membranes and dense tubular system (DTS)-membranes showed the same distribution of Group 1 alpha-subunits. An exception was alpha(q), which was virtually absent in the DTS as were Group 2 subunits. In addition, this compartment showed a doublet for alpha(z). Group 1 alpha-subunits were also found in fractions with the combined secretory granules and in separate dense granules. In addition, alpha16 was found in these granule fractions, but secretion granules were devoid of alpha12. These data reveal a heterogeneous distribution of alpha-subunits in platelet compartments and may indicate that G12 and G16 play different roles in platelets than members of the G(i) and G(s) classes and other members of the G(q) class.
Asunto(s)
Plaquetas/metabolismo , Proteínas de Unión al GTP/sangre , Proteínas de Unión al GTP/química , Compartimento Celular , Membrana Celular/metabolismo , Gránulos Citoplasmáticos/metabolismo , Citosol/metabolismo , Humanos , Membranas Intracelulares/metabolismo , Conformación Proteica , Fracciones Subcelulares/metabolismoRESUMEN
Binding sites on glycoprotein (GP) IIb/IIIa exposed by 0.5 unit/ml alpha-thrombin are insensitive to prostaglandin I2 (PGI2), in contrast with sites exposed by ADP or platelet-activating factor. Here we show that the thrombin receptor agonist peptide (TRAP) (SFLLRN; 15 microM) opens almost the same number of GPIIb/IIIa molecules as 0.5 unit/ml alpha-thrombin (64840 +/- 8920 compared with 81050 +/- 6030 molecules of fibronectin bound/platelet), but these sites rapidly close on addition of PGI2. To investigate whether alpha-thrombin and TRAP initiate different signalling pathways, we measured phospholipase C (PLC)-mediated control of GPIIb/IIIa and its sensitivity to cyclic AMP. Optimal concentrations of alpha-thrombin and TRAP activated PLC maximally, but TRAP induced only about 50% protein kinase C PKC) activation after 10 min stimulation compared with alpha-thrombin. These concentrations also suppressed PGI2-induced cyclic AMP accumulation, with alpha-thrombin inducing complete inhibition and TRAP about 10% less. Direct activation of PKC by phorbol 12-myristate 13-acetate confirmed earlier observations that PGI2-induced cyclic AMP accumulation is partly inhibited via PKC. Applying different concentration of alpha-thrombin, TRAP or a combination of alpha-thrombin and the thrombin receptor inhibitory peptide (TRIP) (Mpr-F-Cha-Cha-RKPNDK-NH2; 800 microM) (Mpr, 3-mercaptopropionic acid; Cha, cyclohexylalanine), we show that the different means of stimulating the thrombin receptor all suppressed PGI2-induced cyclic AMP accumulation via (i) activation of PKC and (ii) activation of the heterotrimeric G-protein, Gi. We conclude that complete inhibition of cyclic AMP accumulation requires activation of both PKC and Gi, as observed with 0.5 unit/ml alpha-thrombin. Although TRAP almost fully exposes GPIIb/IIIa, its activation of PKC is incomplete, enabling PGI2 to raise cyclic AMP concentration from 1.4 +/- 0.7 to 4.1 +/- 1.3 nmol/10(11) platelets (P < 0.005) which is sufficient to close exposed GPIIb/IIIa molecules.